Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis

Daisuke Yamada, Yoshihide Asano, Takehiro Takahashi, Yuri Masui, Naohiko Aozasa, Kaname Akamata, Shinji Noda, Zenshiro Tamaki, Yayoi Tada, Makoto Sugaya, Shinichi Sato, Takafumi Kadono

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Decoy receptor 3 (DcR3) is associated with autoimmunity and altered angiogenesis in certain pathological conditions. We herein measured serum DcR3 levels in 51 patients with systemic sclerosis (SSc) and 19 healthy controls and evaluated their clinical significance in this disorder. Serum DcR3 levels were significantly higher in diffuse cutaneous SSc (dcSSc) patients than in limited cutaneous SSc patients and in healthy controls. In dcSSc, serum DcR3 levels were significantly elevated inpatients with disease durationof ≤6 years compared with healthy controls, but not in those with disease duration of >6 years. Serum DcR3 levels correlated negatively with the percentage of predicted diffusion lung capacity for carbon monoxide and positively with right ventricular systolic pressure. Furthermore, serum DcR3 levels positively correlated with C-reactive protein, erythrocyte sedimentation rate and immunoglobulin G. Collectively, the elevation of serum DcR3 levels is associated with the development of pulmonary arterial hypertension and systemic inflammation in SSc.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalEuropean Journal of Dermatology
Issue number3
Publication statusPublished - 2012 May


  • Angiogenesis
  • Bosentan
  • Cyclophosphamide
  • Decoy receptor 3
  • Systemic sclerosis
  • Vasculopathy


Dive into the research topics of 'Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis'. Together they form a unique fingerprint.

Cite this